Unsupported Price Increase Assessment

ICER

ICER will evaluate selected high-impact drugs with substantial price increases that occurred in 2019. ICER will review changes in the evidence base for each of these drugs and assess whether or not new clinical data exists that could suggest that the drugs could be significantly more beneficial for patients than what was previously understood. ICER will publish the final draft of its first UPI report in October 2020.

For questions or additional information, please contact Laura Cianciolo, Program Manager, at lcianciolo@icer-review.org.

ASSOCIATED MEETING & MATERIALS

ICER

Key Dates

Associated Materials

06/19/2020

06/19/2020 – 07/17/2020
Public Input

01/08/2021
Final Assessment and Report


Key Dates

Associated Materials

01/17/2019

01/17/2019 – 02/13/2019

03/15/2019

03/15/2019

03/15/2019 – 04/19/2019
Open Input Period